JP2020533308A - チューブリシンおよびそれらの中間体の調製のためのプロセス - Google Patents
チューブリシンおよびそれらの中間体の調製のためのプロセス Download PDFInfo
- Publication number
- JP2020533308A JP2020533308A JP2020513753A JP2020513753A JP2020533308A JP 2020533308 A JP2020533308 A JP 2020533308A JP 2020513753 A JP2020513753 A JP 2020513753A JP 2020513753 A JP2020513753 A JP 2020513753A JP 2020533308 A JP2020533308 A JP 2020533308A
- Authority
- JP
- Japan
- Prior art keywords
- formula
- composition
- compound
- substituted
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 *Cc(cc1*=C)cc(*)c1OC(C(C1O)O)OC(*)C1O Chemical compound *Cc(cc1*=C)cc(*)c1OC(C(C1O)O)OC(*)C1O 0.000 description 47
- BWJYJVJIILJBCB-DGCLKSJQSA-N CC(C)[C@@H](C[C@@H](C)c1nc(C(O)=O)c[s]1)N(C)C(OC(C)(C)C)=O Chemical compound CC(C)[C@@H](C[C@@H](C)c1nc(C(O)=O)c[s]1)N(C)C(OC(C)(C)C)=O BWJYJVJIILJBCB-DGCLKSJQSA-N 0.000 description 2
- OZMJKQBMQWNYBS-NWDGAFQWSA-N CC(C)[C@H](C[C@H](c1nc(C(O)=O)c[s]1)O)N(C)C(OC(C)(C)C)=O Chemical compound CC(C)[C@H](C[C@H](c1nc(C(O)=O)c[s]1)O)N(C)C(OC(C)(C)C)=O OZMJKQBMQWNYBS-NWDGAFQWSA-N 0.000 description 2
- ZCMCSYZGDZAHMF-AATRIKPKSA-N CCOC(c1c[s]c(C(/C=C/C(C)C)=O)n1)=O Chemical compound CCOC(c1c[s]c(C(/C=C/C(C)C)=O)n1)=O ZCMCSYZGDZAHMF-AATRIKPKSA-N 0.000 description 2
- JHLVEBNWCCKSGY-UHFFFAOYSA-N CC(C)(C)OC(NC)=O Chemical compound CC(C)(C)OC(NC)=O JHLVEBNWCCKSGY-UHFFFAOYSA-N 0.000 description 1
- OZMJKQBMQWNYBS-KIYNQFGBSA-N CC(C)C(C[C@@H](c1nc(C(O)=O)c[s]1)O)N(C)C(OC(C)(C)C)=O Chemical compound CC(C)C(C[C@@H](c1nc(C(O)=O)c[s]1)O)N(C)C(OC(C)(C)C)=O OZMJKQBMQWNYBS-KIYNQFGBSA-N 0.000 description 1
- OZMJKQBMQWNYBS-VXGBXAGGSA-N CC(C)[C@@H](C[C@H](c1nc(C(O)=O)c[s]1)O)N(C)C(OC(C)(C)C)=O Chemical compound CC(C)[C@@H](C[C@H](c1nc(C(O)=O)c[s]1)O)N(C)C(OC(C)(C)C)=O OZMJKQBMQWNYBS-VXGBXAGGSA-N 0.000 description 1
- SUITWKKZPSZGOO-HZPDHXFCSA-N CCCN([C@H](C[C@H](c1nc(C(OCC)=O)c[s]1)O)C(C)C)C(OC(C)(C)C)=O Chemical compound CCCN([C@H](C[C@H](c1nc(C(OCC)=O)c[s]1)O)C(C)C)C(OC(C)(C)C)=O SUITWKKZPSZGOO-HZPDHXFCSA-N 0.000 description 1
- WBRRJINEWZWGLJ-UHFFFAOYSA-N CCOC(c1c[s]c(C(C)=O)n1)=O Chemical compound CCOC(c1c[s]c(C(C)=O)n1)=O WBRRJINEWZWGLJ-UHFFFAOYSA-N 0.000 description 1
- TZBFSTJLXLLFID-SSESZGDCSA-N CCOC(c1c[s]c(C(C/C(/C(C)C)=N\[S@@](C(C)(C)C)=O)O)n1)=O Chemical compound CCOC(c1c[s]c(C(C/C(/C(C)C)=N\[S@@](C(C)(C)C)=O)O)n1)=O TZBFSTJLXLLFID-SSESZGDCSA-N 0.000 description 1
- YKOVJIFWXRQGNC-UHFFFAOYSA-N CCOC(c1c[s]c(C=O)n1)=O Chemical compound CCOC(c1c[s]c(C=O)n1)=O YKOVJIFWXRQGNC-UHFFFAOYSA-N 0.000 description 1
- ROGDNKUDRQBJBX-ZIAGYGMSSA-N CCOC(c1c[s]c([C@@H](C[C@H](C(C)C)N(C)C(OC(C)(C)C)=O)O)n1)=O Chemical compound CCOC(c1c[s]c([C@@H](C[C@H](C(C)C)N(C)C(OC(C)(C)C)=O)O)n1)=O ROGDNKUDRQBJBX-ZIAGYGMSSA-N 0.000 description 1
- PVGZSUZLFWZUTA-JEUGLTLYSA-N CCOC(c1c[s]c([C@@H](C[C@H](C(C)C)NS(C(C)(C)C)=O)O)n1)=O Chemical compound CCOC(c1c[s]c([C@@H](C[C@H](C(C)C)NS(C(C)(C)C)=O)O)n1)=O PVGZSUZLFWZUTA-JEUGLTLYSA-N 0.000 description 1
- ROGDNKUDRQBJBX-KZUDCZAMSA-N CCOC(c1c[s]c([C@H](CC(C(C)C)N(C)C(OC(C)(C)C)=O)O)n1)=O Chemical compound CCOC(c1c[s]c([C@H](CC(C(C)C)N(C)C(OC(C)(C)C)=O)O)n1)=O ROGDNKUDRQBJBX-KZUDCZAMSA-N 0.000 description 1
- OQLXOLXJMXDXQQ-SFFZSCCOSA-N CC[C@H](C)CC(N(C)[C@@H](C[C@@H](c1nc(C(N[C@H](C[C@H](C)C(O)=O)Cc2ccccc2)=O)c[s]1)OC(C)=O)C(C)C)=O Chemical compound CC[C@H](C)CC(N(C)[C@@H](C[C@@H](c1nc(C(N[C@H](C[C@H](C)C(O)=O)Cc2ccccc2)=O)c[s]1)OC(C)=O)C(C)C)=O OQLXOLXJMXDXQQ-SFFZSCCOSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023022825A JP2023053386A (ja) | 2017-09-08 | 2023-02-16 | チューブリシンおよびそれらの中間体の調製のためのプロセス |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762556234P | 2017-09-08 | 2017-09-08 | |
| US62/556,234 | 2017-09-08 | ||
| PCT/US2018/050095 WO2019051322A1 (en) | 2017-09-08 | 2018-09-07 | PROCESS FOR THE PREPARATION OF TUBULYSINS AND INTERMEDIATES THEREOF |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023022825A Division JP2023053386A (ja) | 2017-09-08 | 2023-02-16 | チューブリシンおよびそれらの中間体の調製のためのプロセス |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020533308A true JP2020533308A (ja) | 2020-11-19 |
| JP2020533308A5 JP2020533308A5 (https=) | 2021-10-14 |
Family
ID=63963374
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020513753A Ceased JP2020533308A (ja) | 2017-09-08 | 2018-09-07 | チューブリシンおよびそれらの中間体の調製のためのプロセス |
| JP2023022825A Pending JP2023053386A (ja) | 2017-09-08 | 2023-02-16 | チューブリシンおよびそれらの中間体の調製のためのプロセス |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023022825A Pending JP2023053386A (ja) | 2017-09-08 | 2023-02-16 | チューブリシンおよびそれらの中間体の調製のためのプロセス |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11389543B2 (https=) |
| EP (1) | EP3679036A1 (https=) |
| JP (2) | JP2020533308A (https=) |
| KR (1) | KR20200051733A (https=) |
| CN (1) | CN111601803A (https=) |
| AU (1) | AU2018329951B2 (https=) |
| BR (1) | BR112020004495A2 (https=) |
| CA (1) | CA3073766A1 (https=) |
| EA (1) | EA202090670A1 (https=) |
| IL (1) | IL272837B2 (https=) |
| MA (1) | MA50124A (https=) |
| MX (1) | MX2020001928A (https=) |
| SG (1) | SG11202001543XA (https=) |
| TW (2) | TWI820038B (https=) |
| WO (1) | WO2019051322A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021536475A (ja) * | 2018-09-07 | 2021-12-27 | シージェン インコーポレイテッド | チューブリシンおよびそれらの中間体の調製のための代替プロセス |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200051733A (ko) * | 2017-09-08 | 2020-05-13 | 시애틀 지네틱스, 인크. | 튜불리신 및 그 중간물의 제조 공정 |
| BR112023018676A2 (pt) | 2021-03-18 | 2023-10-10 | Seagen Inc | Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008106080A2 (en) * | 2007-02-27 | 2008-09-04 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Synthesis of desacetoxytubulysin h and analogs thereof |
| JP2015531794A (ja) * | 2012-09-17 | 2015-11-05 | オントケム ゲーエムベーハーＯｎｔｏｃｈｅｍ Ｇｍｂｈ | 受容体リガンドにリンクされる細胞傷害分子 |
| WO2016040684A1 (en) * | 2014-09-11 | 2016-03-17 | Seattle Genetics, Inc | Targeted delivery of tertiary amine-containing drug substances |
| WO2016090050A1 (en) * | 2014-12-03 | 2016-06-09 | Genentech, Inc. | Quaternary amine compounds and antibody-drug conjugates thereof |
| WO2016138288A1 (en) * | 2015-02-25 | 2016-09-01 | William Marsh Rice University | Desacetoxytubulysin h and analogs thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10230872A1 (de) * | 2002-07-09 | 2004-01-22 | Morphochem AG Aktiengesellschaft für kombinatorische Chemie | Verfahren zur Herstellung von substituierten Thiazol-2-ylmethylestern |
| ES2708763T3 (es) | 2005-07-07 | 2019-04-11 | Seattle Genetics Inc | Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C |
| EP2032606B1 (en) | 2006-05-30 | 2013-11-27 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
| ES2649941T3 (es) | 2007-02-23 | 2018-01-16 | Aileron Therapeutics, Inc. | Aminoácidos sustituidos para preparar péptidos macrocíclicos unidos a triazol |
| AU2013229786B2 (en) | 2012-03-08 | 2017-06-22 | Halozyme, Inc. | Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof |
| CN104640572B (zh) | 2012-05-15 | 2018-04-27 | 索伦托医疗有限公司 | 药物偶联物，偶联方法，及其用途 |
| WO2013173337A2 (en) | 2012-05-15 | 2013-11-21 | Seattle Genetics, Inc. | Self-stabilizing linker conjugates |
| MX369022B (es) | 2013-05-31 | 2019-10-25 | Genentech Inc | Anticuerpos anti-ácido teicoico de la pared celular y conjugados. |
| RU2687044C2 (ru) | 2013-05-31 | 2019-05-06 | Дженентек, Инк. | Антитела против стеночной тейхоевой кислоты и их конъюгаты |
| KR20200051733A (ko) * | 2017-09-08 | 2020-05-13 | 시애틀 지네틱스, 인크. | 튜불리신 및 그 중간물의 제조 공정 |
-
2018
- 2018-09-07 KR KR1020207009940A patent/KR20200051733A/ko not_active Ceased
- 2018-09-07 EP EP18792575.5A patent/EP3679036A1/en not_active Withdrawn
- 2018-09-07 MA MA050124A patent/MA50124A/fr unknown
- 2018-09-07 US US16/645,369 patent/US11389543B2/en active Active
- 2018-09-07 TW TW107131484A patent/TWI820038B/zh not_active IP Right Cessation
- 2018-09-07 BR BR112020004495-4A patent/BR112020004495A2/pt not_active Application Discontinuation
- 2018-09-07 EA EA202090670A patent/EA202090670A1/ru unknown
- 2018-09-07 IL IL272837A patent/IL272837B2/en unknown
- 2018-09-07 MX MX2020001928A patent/MX2020001928A/es unknown
- 2018-09-07 WO PCT/US2018/050095 patent/WO2019051322A1/en not_active Ceased
- 2018-09-07 SG SG11202001543XA patent/SG11202001543XA/en unknown
- 2018-09-07 TW TW112136966A patent/TW202428569A/zh unknown
- 2018-09-07 CA CA3073766A patent/CA3073766A1/en active Pending
- 2018-09-07 AU AU2018329951A patent/AU2018329951B2/en not_active Ceased
- 2018-09-07 JP JP2020513753A patent/JP2020533308A/ja not_active Ceased
- 2018-09-07 CN CN201880062053.2A patent/CN111601803A/zh active Pending
-
2022
- 2022-06-08 US US17/835,841 patent/US20220323601A1/en not_active Abandoned
-
2023
- 2023-02-16 JP JP2023022825A patent/JP2023053386A/ja active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008106080A2 (en) * | 2007-02-27 | 2008-09-04 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Synthesis of desacetoxytubulysin h and analogs thereof |
| JP2015531794A (ja) * | 2012-09-17 | 2015-11-05 | オントケム ゲーエムベーハーＯｎｔｏｃｈｅｍ Ｇｍｂｈ | 受容体リガンドにリンクされる細胞傷害分子 |
| WO2016040684A1 (en) * | 2014-09-11 | 2016-03-17 | Seattle Genetics, Inc | Targeted delivery of tertiary amine-containing drug substances |
| WO2016090050A1 (en) * | 2014-12-03 | 2016-06-09 | Genentech, Inc. | Quaternary amine compounds and antibody-drug conjugates thereof |
| WO2016138288A1 (en) * | 2015-02-25 | 2016-09-01 | William Marsh Rice University | Desacetoxytubulysin h and analogs thereof |
Non-Patent Citations (3)
| Title |
|---|
| "2-[(1S,3R)-1-ACETYLOXY-4-METHYL-3-[METHYL-[(2-METHYLPROPAN-2-YL)OXYCARBONYL]AMINO]PENTYL]-1,3-THIAZO", [ONLINE], JPN5021001282, 21 March 2013 (2013-03-21), pages 1 - 9, ISSN: 0005061983 * |
| PARKER, JEREMY S. ET AL: "The Development and Scale-Up of an Antibody Drug Conjugate Tubulysin Payload", ORGANIC PROCESS RESEARCH & DEVELOPMENT, vol. 21(10),, JPN6022039697, 2017, pages 1602 - 1609, ISSN: 0005061984 * |
| 山中 宏、宮崎 浩、村上尚道: "光学活性体のプレパレーション・生理活性・利用", 季刊 化学総説 光学異性体の分離, JPN3011000610, 10 June 1999 (1999-06-10), JP, pages 8 - 9, ISSN: 0005061985 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021536475A (ja) * | 2018-09-07 | 2021-12-27 | シージェン インコーポレイテッド | チューブリシンおよびそれらの中間体の調製のための代替プロセス |
| JP7511543B2 (ja) | 2018-09-07 | 2024-07-05 | シージェン インコーポレイテッド | チューブリシンおよびそれらの中間体の調製のための代替プロセス |
Also Published As
| Publication number | Publication date |
|---|---|
| MA50124A (fr) | 2020-07-15 |
| BR112020004495A2 (pt) | 2020-09-08 |
| IL272837A (en) | 2020-04-30 |
| EA202090670A1 (ru) | 2020-07-28 |
| CA3073766A1 (en) | 2019-03-14 |
| TW202428569A (zh) | 2024-07-16 |
| IL272837B1 (en) | 2024-02-01 |
| CN111601803A (zh) | 2020-08-28 |
| KR20200051733A (ko) | 2020-05-13 |
| AU2018329951B2 (en) | 2023-12-14 |
| TWI820038B (zh) | 2023-11-01 |
| EP3679036A1 (en) | 2020-07-15 |
| US20220323601A1 (en) | 2022-10-13 |
| WO2019051322A1 (en) | 2019-03-14 |
| AU2018329951A1 (en) | 2020-04-16 |
| MX2020001928A (es) | 2020-03-24 |
| JP2023053386A (ja) | 2023-04-12 |
| US11389543B2 (en) | 2022-07-19 |
| IL272837B2 (en) | 2024-06-01 |
| US20200297864A1 (en) | 2020-09-24 |
| SG11202001543XA (en) | 2020-03-30 |
| TW201920128A (zh) | 2019-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7073266B2 (ja) | Ｐｅｇ化薬物リンカー及びその中間体を調製するためのプロセス | |
| JP6824931B2 (ja) | 第３級アミン含有薬物物質の標的送達 | |
| JP2022518743A (ja) | 抗体－薬物コンジュゲート用のグリコシド含有ペプチドリンカー | |
| EA014872B1 (ru) | Азиридинилэпотилоновые соединения | |
| JP2023053386A (ja) | チューブリシンおよびそれらの中間体の調製のためのプロセス | |
| CN116964076A (zh) | 化合物或其盐、以及由它们得到的抗体 | |
| JP2021536475A (ja) | チューブリシンおよびそれらの中間体の調製のための代替プロセス | |
| HK40036588A (en) | Process for the preparation of tubulysins and intermediates thereof | |
| HK40045709A (en) | Alternative processes for the preparation of tubulysins and intermediates thereof | |
| EA047735B1 (ru) | Способ получения пегилированных соединений лекарственный препарат-линкер и их промежуточных соединений | |
| HK40009733A (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210906 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210906 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220810 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220916 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20221215 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230216 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230519 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230817 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231018 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20231124 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240322 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20240402 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240719 |
|
| A045 | Written measure of dismissal of application [lapsed due to lack of payment] |
Free format text: JAPANESE INTERMEDIATE CODE: A045 Effective date: 20241122 |